JPRN-UMIN000023917已完成未知
Evaluation of the effects of OATP1B1*15 on the plasma concentrations of endogenous compounds (metabolome analysis) - Exploration for the biomarkers for OATP1B1*15
Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University0 个研究点目标入组 26 人开始时间: 2016年9月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 45years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The investigators must ensure that all subjects being considered meet the following exclusion criteria or conditions: 1) history of allergy to any drugs 2) medical attention within 2 months prior to participation 3) donation of 200 mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4) donation of 400 mL or more of blood within 12 weeks prior to participation 5) recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6) history of drug abuse 7) alcohol abuse. 8) lactose intolerance 9) taking drugs or healthy foods which may affect drug metabolism
研究者
相似试验
招募中
不适用
Analysis of the effect of OATP1B3 genomic abnormality on hepatic ICG clearancechronic hepatitis CJPRN-UMIN000032781Tokai University37
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSEUCTR2005-002892-34-IEAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-GRAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-PTAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-EEAstraZeneca SAS1,150